[Current aspects of heart-kidney interactions : Summary of important clinical studies from 2020].
Insa E EmrichMert TokcanHussam Al GhoraniVedat SchwengerFelix MahfoudPublished in: Herz (2021)
Patients with chronic kidney diseases show an increased cardiovascular morbidity and mortality. Last year a number of important studies on heart-kidney interaction were published, which are summarized and discussed in this article. In the DAPA-CKD study and the SCORED study two different sodium-glucose linked transporter 2 (SGLT2) inhibitors (dapagliflozin and sotagliflozin) were found to improve the prognosis of patients with chronic kidney diseases with and without diabetes. The results of the randomized study on the new mineralocorticoid receptor antagonist finerenon (FIDELIO-DKD) also provided a very promising novel treatment approach for patients with diabetic nephropathy. The published data of the ISCHEMIA-CKD study in patients with coronary heart disease and investigations on the influence of transcatheter aortic valve implantation (TAVI) on renal function as well as another study on acute kidney failure after MitraClip® (Abbott, Chicago, IL, USA) implantation provide important indications for future treatment recommendations. The optimal timing of the initiation of kidney replacement therapy in patients with acute kidney damage in intensive care medicine was investigated in two randomized studies, which are correspondingly discussed.
Keyphrases
- transcatheter aortic valve implantation
- replacement therapy
- heart failure
- type diabetes
- cardiovascular disease
- oxidative stress
- randomized controlled trial
- chronic kidney disease
- adipose tissue
- machine learning
- coronary artery disease
- systematic review
- open label
- smoking cessation
- aortic valve replacement
- liver failure
- transcatheter aortic valve replacement
- current status
- left ventricular
- big data
- double blind
- acute respiratory distress syndrome
- ejection fraction
- drug induced